Navigation Links
Accera, Inc. Announces Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting

pound's disease modifying potential. Taken in addition to an existing AD treatment, AC-1202 was well tolerated, making it a promising co-therapeutic candidate for the chronic treatment of the disease.

Dr. Lauren Costantini is presenting the abstract, "Clinical Efficacy of AC-1202 in Mild to Moderate Alzheimer's Disease" at the Late Breaking Science session today at 3:45 p.m. EDT. The plenary session will be held at 5:15 p.m. EDT on Friday, May 4.

The trial was conducted at 25 centers across the United States, and all subjects were given the opportunity to participate in a six-month open-label extension upon completion of the three-month blinded study. The results of the open-label extension will be presented at the Alzheimer's Association's International Prevention Conference in early June.

About AC-1202

Brain imaging techniques performed on AD patients reveal a dramatically decreased uptake of glucose, the brain's preferred source of energy. AC-1202 is an orally available, liquid compound that is efficiently converted by the liver into ketone bodies, an alternative energy source that the brain can metabolize even when it cannot process glucose. Thus preserving the glucose- deprived brain cells, AC-1202 has disease modifying potential in AD and a number other neurodegenerative diseases characterized by neuronal metabolism. The potentially neuroprotective mechanism of this first-in-class compound is also being evaluated in age-associated memory impairment, Parkinson's disease, and canine cognitive dysfunction.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biopharmaceutical company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, AC-1202, is a first- in-class molecule currently in Phase II clinical trials for Alzheimer's disease and age-associated memory impairment. A key element of Accera's strategy is to develop AC-1202 and other small molecule com
'"/>




Page: 1 2 3

Related medicine technology :

1. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/21/2014)... , Aug. 21, 2014   Royal Philips ... today announced it has received 510(k) clearance from ... its precision planning application for Transcatheter Aortic-Valve Implantation ... application provides interventionalists with pre-procedural, high-precision positioning to ... TAVI planning application is available as part of ...
(Date:8/21/2014)... 2014   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced positive results from a randomized, double-blind ... CCH) for the treatment of edematous fibrosclerotic panniculopathy ... 2a trial, all three doses of CCH (low ... improvement in the appearance of cellulite as measured ...
(Date:8/20/2014)... The National Association of Drug Diversion ... by the real-time, pseudoephedrine (PSE) blocking system in ... Exchange (NPLEx), automatically blocks unlawful pseudoephedrine sales and ... and make arrests. Data released by NPLEx shows ... blocked the sale of more than 7,481 boxes of ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ... receiving concomitant systemic antibiotics in two Phase 3 clinical ... the treatment of adult patients with Clostridium difficile ... 1 issue of Clinical Infectious Diseases (CID). ...
... Aug. 16, 2011 Marshall Edwards, Inc. (Nasdaq: ... clinical development of novel therapeutics targeting cancer metabolism, announced ... ME-143 (formerly NV-143), the Company,s lead NADH oxidase inhibitor, ... Administration (FDA). The Company plans to initiate a Phase ...
Cached Medicine Technology:Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 2Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 3Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 4Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 5Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 6Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143 2Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143 3
(Date:8/22/2014)... 22, 2014 Dealing with a drug or ... the addict is a child. Adolescent substance abuse has been ... long time. But a new helpline is now providing a ... youth rehab for something like a teen drug addiction ... to help make a positive impact in the community. By ...
(Date:8/22/2014)... According to the market research report "Blind ... (ACC) System Market for Passenger Cars; by Geography ... by MarketsandMarkets, classifies and defines the automotive BSD ... and value. The report highlights potential growth opportunities ... review of the market drivers, restrains, growth indicators, ...
(Date:8/21/2014)... Petersburg, FL (PRWEB) August 22, 2014 The ... behind those fine lines, wrinkles and sagging of skin. ... loss. , "By age 40, the body has lost about ... has lost about 45%," says Kathy Heshelow, founder of Sublime ... with less of it - well, we know what happens." ...
(Date:8/21/2014)... York, NY (PRWEB) August 21, 2014 ... can often have larger discounts for specific protection plans, ... is now helping consumers to quote life insurance from ... , The local agents that appear inside of ... offer a fast method of price reviews this year. ...
(Date:8/21/2014)... 21, 2014 AVEC Health Solutions, ... the addition of Kerry Gillespie as Chief Executive ... management experience, Gillespie brings an extremely robust background ... management positions with prominent industry leading organizations across ... President of Triad Isotopes, Inc. a private nuclear ...
Breaking Medicine News(10 mins):Health News:Cincinnati’s New Troubled Teen Helpline is Making a Difference in the Community 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 3Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 4Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 2Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Kerry Gillespie Appointed as Chief Executive Officer of AVEC Health Solutions 2
... was issued,today by the law firm of Schiffrin Barroway Topaz ... class action lawsuit was filed in the,United States District Court ... of securities of Healthways Inc. (Nasdaq: HWAY ),("Healthways" or ... (the "Class Period")., If you wish to discuss this ...
... The University of Illinois at Chicago is one of ... Norway to participate in the Clinical Islet Transplant Consortium ... researchers have begun clinical studies to test new approaches ... and fewer side effects for adults with difficult-to-control type ...
... U.S. Senate to vote soon on legislation that ... New Hampshire, WASHINGTON, July 8 Seniors ... to the Medicare Advantage,program in legislation being considered ... cut $6.6 million from the Medicare Advantage program ...
... Pittsburgh-led researchers could provide new insight into how ... arteriovenous malformations (AVMs)develop in humans, as reported in ... . , Led by Beth Roman, an assistant ... Arts and Sciences, the team created the first ...
... rates no different than ,watchful waiting, study shows , , ... therapy used for localized prostate cancer may not bestow ... with a simple "wait-and-see" approach. , Men taking androgen ... promote tumor growth, even had a slightly lower ...
... From the Committee to Reduce Infection Deaths (RID), ... to be,proud of," says Betsy McCaughey, Chairman of the ... of New York State. The New York,State Hospital-Acquired Infection ... performance with national infection,rate averages, and finds the state ...
Cached Medicine News:Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:UIC in NIH-funded islet transplantation study for type 1 diabetes 2Health News:New Hampshire Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Pitt-led research provides insight into development of congenital circulatory defects 2Health News:Hormone Therapy Shows Little Benefit Against Prostate Cancer 2Health News:Hormone Therapy Shows Little Benefit Against Prostate Cancer 3Health News:It's the Same Old Song: 'Accentuate the Positive' as New York State Department of Health Releases Statewide Hospital Infection Rates 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: